Engineers Gate Manager’s Phathom Pharmaceuticals PHAT Stock Holding History

Engineers Gate Manager’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.28M	Buy	118,257 +44,409	+60%	+$507K	0.02%	935
2026 Q1	$820K	Buy	73,848 +29,590	+67%	+$374K	0.01%	1149
2025 Q4	$734K	Buy	+44,258	New	+$632K	0.01%	1184
2025 Q2	–	Sell	-26,623	Closed	-$167K	–	2452
2025 Q1	$167K	Sell	26,623 -5,877	-18%	-$35.7K	﹤0.01%	1924
2024 Q4	$264K	Buy	+32,500	New	+$402K	﹤0.01%	1763
2023 Q4	–	Sell	-12,888	Closed	-$134K	–	2178
2023 Q3	$134K	Buy	+12,888	New	+$177K	﹤0.01%	1563
2021 Q3	–	Sell	-14,310	Closed	-$484K	–	1896
2021 Q2	$484K	Buy	14,310 +5,054	+55%	+$181K	0.03%	846
2021 Q1	$348K	Buy	+9,256	New	+$387K	0.02%	1223

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Engineers Gate Manager's PHAT Position: Q2 2026 in Review

Engineers Gate Manager increased its Phathom Pharmaceuticals (PHAT) stake by 60% in Q2 2026, buying an estimated $507K and bringing the position to 118,257 shares worth $1.28M. The position accounts for 0.02% of the portfolio, ranked #935.

Engineers Gate Manager first reported a position in PHAT in Q1 2021 and has held it in 8 quarters since. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Engineers Gate Manager held 118,257 shares of Phathom Pharmaceuticals worth $1.28M as of Q2 2026.
Engineers Gate Manager bought 44,409 Phathom Pharmaceuticals shares in Q2 2026, an estimated $507K.
Phathom Pharmaceuticals made up 0.02% of Engineers Gate Manager's portfolio in Q2 2026, its #935 holding.
Engineers Gate Manager first reported a position in Phathom Pharmaceuticals in Q1 2021 and has held it in 8 quarters since.
162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.